MedTrace Logo

A Study of Adalimumab to Treat Sarcoidosis of the Skin

NCT00274352 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2013-05-22

No results posted yet for this study

Summary

The purpose of this study is to determine if adalimumab is an effective for the skin manifestations of sarcoidosis.

Conditions

  • Sarcoidosis

Interventions

DRUG

adalimumab

Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Virginia Clinical Research, Inc.

    collaborator OTHER

  • Pariser, Robert J., M.D.

    lead OTHER

Principal Investigators

  • Robert J Pariser, MD · Eastern Virginia Medical School

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00274352 on ClinicalTrials.gov